Recurrent Indolent Adult Non-Hodgkin Lymphoma (DBCOND0041835)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00764517	Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma	Cladribine Rituximab Vorinostat	treatment	2	completed
NCT00789776	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT03147885	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	Escitalopram Selinexor	treatment	1 / 2	recruiting
NCT04447716	An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment	Hyaluronidase (human recombinant) Lenalidomide Rituximab Venetoclax	treatment	1	recruiting
NCT03019640	Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	Allogeneic natural killer cells Beta-D-Glucose Carmustine Cytarabine Etoposide Filgrastim Lenalidomide Mechlorethamine Natural Killer Cell Rituximab	treatment	2	completed
NCT02928510	Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma	Idelalisib	Not Available	Not Available	terminated